GlassScriptPhysician profile
Blaine S Cameron
NPI 1912950023
$5,190.92
in general payments reported to CMS, 2019-2025
35 companies · $712 in 2025
The $712 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $97.35 · 2021: $254 · 2022: $1,784 · 2023: $854 · 2024: $901 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,466.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,840.33 | 2019-2025 | Relistor |
| Medtronic, INC. | $622.62 | 2022 | |
| Vertos Medical, INC. | $543.55 | 2022-2024 | Mild Device Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $273.33 | 2022 | |
| Collegium Pharmaceutical, INC. | $255.07 | 2019-2025 | Xtampza, Belbuca |
| Scilex Pharmaceuticals INC. | $251.98 | 2019-2024 | Ztlido |
| Pfizer INC. | $158.63 | 2023-2025 | |
| Amgen INC. | $153.41 | 2021 | |
| Biodelivery Sciences International, INC. | $110.68 | 2019-2021 | |
| Abbvie INC. | $103.35 | 2022-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $95.15 | 2023-2024 | Rybelsus |
| Idorsia Pharmaceuticals US INC | $83.32 | 2022-2024 | Quviviq |
| Surgentec | $72.00 | 2023 | Ion Facet Screw System, Tilink |
| Abbott Laboratories | $70.96 | 2019-2023 | Proclaim |
| Axsome Therapeutics, INC. | $58.14 | 2025 | Symbravo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $55.71 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $50.72 | 2019-2022 | |
| Alvogen INC | $50.23 | 2022 | |
| Daiichi Sankyo INC. | $40.69 | 2019 | |
| Medtronic USA, INC. | $40.51 | 2019 | |
| Valinor Pharma, LLC | $40.31 | 2023 | Movantik |
| Ibsa Pharma INC. | $22.90 | 2023 | Tirosint, Licart |
| Vertex Pharmaceuticals Incorporated | $18.52 | 2025 | |
| Hikma Pharmaceuticals USA | $18.41 | 2022 | |
| Relievant Medsystems, INC. | $17.49 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.74 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.52 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.63 | 2023 | Horizant |
| Lilly USA, LLC | $14.39 | 2023 | Emgality |
| Avanos Medical | $14.33 | 2019 | |
| Protega Pharmaceutials INC | $14.32 | 2025 | Roxybond |
| Nevro Corp. | $13.49 | 2024 | Senza |
| Camber Spine Technologies LLC | $13.17 | 2023 | |
| Tersera Therapeutics LLC | $12.56 | 2020 | |
| Boston Scientific Corporation | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blaine Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.